Eric Coldwell
Stock Analyst at Baird
(3.85)
# 636
Out of 5,124 analysts
164
Total ratings
61.54%
Success rate
5.9%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Initiates: Outperform | $48 | $47.30 | +1.48% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $948.68 | -2.29% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $189.21 | +5.17% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $187.49 | +37.61% | 19 | Oct 29, 2025 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $14.67 | -4.57% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $150.59 | +48.75% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $190.71 | +1.73% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $226.32 | -10.30% | 13 | Aug 13, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $277.20 | +8.95% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $542.04 | -9.60% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $10.65 | +50.23% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $66.06 | -31.88% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $78.35 | -15.76% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.89 | +5,088.95% | 4 | Nov 10, 2017 |
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $47.30
Upside: +1.48%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $948.68
Upside: -2.29%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $189.21
Upside: +5.17%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $187.49
Upside: +37.61%
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $14.67
Upside: -4.57%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $150.59
Upside: +48.75%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $190.71
Upside: +1.73%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $226.32
Upside: -10.30%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $277.20
Upside: +8.95%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $542.04
Upside: -9.60%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $10.65
Upside: +50.23%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $66.06
Upside: -31.88%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $78.35
Upside: -15.76%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.89
Upside: +5,088.95%